Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.32 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2588591 | 0.88 | MAPT (0.34) | ALOX5APFEN1PDE4BPDE4DTUBB1 | |
| SCHEMBL2591532 | 0.86 | MEN1 (0.36) | ALOX5APFEN1TUBB1MAPT | |
| SCHEMBL14736781 | 0.84 | TUBB1 (0.40) | TUBB1CA1CA2CA4CA6 | |
| SCHEMBL2589057 | 0.84 | ALDH1A1 (0.33) | ALOX5APFEN1PDE4BPDE4DTUBB1 | |
| SCHEMBL2584271 | 0.84 | ALDH1A1 (0.41) | ALOX5APFEN1TUBB1HPGDMAPT | |
| SCHEMBL2590931 | 0.82 | ALOX5AP (0.33) | ALOX5APFEN1PDE4BPDE4DTUBB1 | |
| SCHEMBL2582074 | 0.80 | TSHR (0.48) | PDE4DHPGDCASP1PTPN1 | |
| SCHEMBL2583910 | 0.80 | NCOA1 (0.40) | TUBB1HPGDMAPT | |
| SCHEMBL6899392 | 0.79 | MAPT (0.40) | TUBB1F2RL3HPGDPTPN1MAPT | |
| SCHEMBL2591340 | 0.78 | NUDT1 (0.35) | ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563770-B1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2016-03-23 | — | — | EP | disclosed |
| US-9051290-B2 | Biaryl phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-06-09 | — | — | US | disclosed |
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-03-07 | — | — | US | disclosed |
| EP-2563770-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011134468-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE4A | ALOX5AP 1808/4885FEN1 342/4885PDE4B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.